論文数：23

• Ameliorating Role of Hydrogen-Rich Water Against NSAID-Induced Enteropathy via Reduction of ROS and Production of Short-Chain Fatty Acids.
  Akita Y, Higashiyama M, Kurihara C, Ito S, Nishii S, Mizoguchi A, Inaba K, Tanemoto R, Sugihara N, Hanawa Y, Wada A, Horiuchi K, Okada Y, Narimatsu K, Komoto S, Tomita K, Takei F, Satoh Y, Saruta M, Hokari R
  Dig Dis Sci. 2022 Dec 7:1-11　　DOI:10.1007/s10620-022-07781-5　

• Comparison of the effects of individual symptoms of gastroesophageal reflux disease co-existing functional dyspepsia on patients' daily lives: A prospective, observational study
  Tatsuya Nakada, Kimio Isshi, Nobuyuki Matsuhashi, Katsuhiko Iwakiri, Takeshi Kamiya, Noriaki Manabe, Kazuhide Higuchi, Takashi Joh, Atsushi Oshio, Maiko Ogawa, Atsushi Hokari, Masayuki Saruta, Ken Haruma, Koji Nakada
  JGH Open . 2022 Nov 5;6(12):886-893.　　DOI:10.1002/jgh3.12837.　

• 高齢者潰瘍性大腸炎の疫学・経過・併存症
  猿田 雅之
  日本消化器病学会雑誌2022年119巻11号p.984-991　　DOI:10.11405/nisshoshi.119.984.　Japanese article

• Positioning and Usefulness of Biomarkers in Inflammatory Bowel Disease.
  Sakurai T, Saruta M
  Digestion. 2022 Nov 18:1-12.　　DOI:10.1159/000527846　

• Dysbiosis of the Fecal and Biliary Microbiota in Biliary Tract Cancer.
  Ito Z, Koido S, Kato K, Odamaki T, Horiuchi S, Akasu T, Saruta M, Hata T, Kumagai Y, Fujioka S, Misawa T, Xiao JZ, Sato N, Ohkusa T
  Cancers (Basel). 2022 Oct 31;14(21):5379　　DOI:10.3390/cancers14215379.　

• Potential significance of uncovered self-expandable metal stents for distal malignant biliary obstruction: A propensity score-adjusted competing risk regression analysis
  Yuichi Torisu, Masafumi Chiba, Masayuki Kato, Yuji Kinoshita, Takafumi Akasu, Tomoya Kanai, Yoichi Tomita, Nana Shimamoto, Takahiro Abe, Keisuke Kanazawa, Shintaro Tsukinaga, Masanori Nakano, Chisato Saeki, Kazuki Sumiyama, Masayuki Saruta
  DEN Open　　DOI:10.1002/deo2.166.　

• Recent Topics in the Pathophysiology and Medical Management of Inflammatory Bowel Disease
  Motohiro Esaki, Masayuki Saruta
  Digestion　　DOI:10.1159/000526304.　

• Serum Insulin-Like Growth Factor 1 Levels, Facture Risk Assessment Tool Scores and Bone Disorders in Patients with Primary Biliary Cholangitis
  Chisato Saeki, Tsunekazu Oikawa, Kaoru Ueda, Masanori Nakano, Yuichi Torisu, Masayuki Saruta, Akihito Tsubota
  Diagnostics (Basel) . 2022 Aug 12;12(8):1957.　　DOI:10.3390/diagnostics12081957　

• Characteristics of adult patients newly diagnosed with Crohn's disease: interim analysis of the nation-wide inception cohort registry study of patients with Crohn's disease in Japan (iCREST-CD)
  Masayuki Saruta et al.
  J Gastroenterol . 2022 Aug 5.　　DOI:10.1007/s00535-022-01907-2　

• Protein Kinase C Delta Is a Novel Biomarker for Hepatocellular Carcinoma
  Tsunekazu Oikawa, Kohji Yamada, Akihito Tsubota, Chisato Saeki, Naoko Tago, Chika Nakagawa, Kaoru Ueda, Hiroshi Kamioka, Tomohiko Taniai, Koichiro Haruki, Masanori Nakano, Yuichi Torisu, Toru Ikegami, Kiyotsugu Yoshida, Masayuki Saruta
  Gastro Hep Advances Volume 2, Issue 1, 2023, Pages 83-95　　DOI:10.1016/j.gastha.2022.07.020　

• Centrilobular zonal necrosis is a unique subtype of autoimmune hepatitis: A cohort study
  Kaoru Ueda, Yoshio Aizawa, Chika Kinoshita, Tomohisa Nagano, Jinya Ishida, Chisato Saeki, Tsunekazu Oikawa, Toru Harada, Atsushi Hokari, Masayuki Saruta
  Medicine (Baltimore) . 2022 Jul 22;101(29):e29484　　DOI:10.1097/MD.0000000000029484.　

• Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon ～
  Masayuki Saruta et al.
  Int J Clin Oncol . 2022 Jul 21　　DOI:10.1007/s10147-022-02208-7　

• Safety and efficacy of pentazocine-midazolam combination for pain and anxiety relief in radiofrequency ablation therapy for hepatocellular carcinoma
  Masanori Nakano, Yuichi Torisu, Chika Nakagawa, Kaoru Ueda, Tomoya Kanai, Chisato Saeki, Tsunekazu Oikawa, Masayuki Saruta
  JGH Open . 2022 Jul 17;6(8):569-576　　DOI:10.1002/jgh3.12788　

• Adrenomedullin for biologic-resistant Crohn's disease: A randomized, double-blind, placebo-controlled phase 2a clinical trial
  Masayuki Saruta et al
  J Gastroenterol Hepatol . 2022 Jul 15　　DOI:10.1111/jgh.15945　

• Bowel frequency (night) and urgent defecation are improved by budesonide foam in patients with ulcerative colitis: a retrospective observational study
  Ryosuke Miyazaki, Toshiyuki Sakurai, Mariko Shimada, Yuko Iwashita, Naoki Shibuya, Yoshihiro Akita, Haruna Miyashita, Yuki Maruyama, Masayuki Saruta
  BMC Gastroenterol . 2022 Jun 24;22(1):310　　DOI:10.1186/s12876-022-02388-6　

• The stimulatory effect of fusobacteria on dendritic cells under aerobic or anaerobic conditions
  Shigeo Koido, Sankichi Horiuchi, Shin Kan, Tsuuse Bito, Zensho Ito, Kan Uchiyama, Masayuki Saruta, Nobuhiro Sato, Toshifumi Ohkusa
  Sci Rep . 2022 Jun 23;12(1):10698　　DOI:10.1038/s41598-022-14934-z.　

• Efficacy of the pocket-creation method with a traction device in endoscopic submucosal dissection for residual or recurrent colorectal lesions
  Daisuke Ide, Tomohiko Richard Ohya, Mitsuaki Ishioka, Yuri Enomoto, Eisuke Nakao, Yuki Mitsuyoshi, Junki Tokura, Keigo Suzuki, Seiichi Yakabi, Chihiro Yasue, Akiko Chino, Masahiro Igarashi, Akio Nakashima, Masayuki Saruta, Shoichi Saito, Junko Fujisaki
  Clin Endosc 　　DOI:10.5946/ce.2022.009.　

• Identification of circulating microRNAs as potential biomarkers for hepatic necroinflammation in patients with autoimmune hepatitis
  Chisato Saeki, Juntaro Matsuzaki, Masahiko Kuroda, Koji Fujita, Makiko Ichikawa, Satoko Takizawa, Keiko Takano, Tsunekazu Oikawa, Yasuni Nakanuma, Masayuki Saruta, Takahiro Ochiya, Akihito Tsubota
  BMJ Open Gastroenterol . 2022 Apr;9(1)　　DOI:10.1136/bmjgast-2022-000879.　

• Poorly Differentiated Neuroendocrine Carcinoma of Unknown Primary with Metastasis to the Testis: A Case Report
  Momoko Sano Masaaki Noguchi, Akiyoshi Kinoshita, Mayo Nakamura, Kazuhiko Koike, Masayuki Saruta
  Case Rep Oncol . 2022 Apr 8;15(1):388-393　　DOI:10.1159/000523989.　

• Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial
  Toshifumi Hibi, et al.(including Masayuki Saruta)
  Intest Res . 　　DOI:10.5217/ir.2021.00143　

• The Geriatric Nutritional Risk Index Predicts Tolerability of Lenvatinib in Patients With Hepatocellular Carcinoma
  Akiyoshi Kinoshita, Noriko Hagiwara, Akiyuki Osawa, Takafumi Akasu, Yoshihiro Matsumoto, Kaoru Ueda, Chisato Saeki, Tsunekazu Oikawa, Kazuhiko Koike, Masayuki Saruta
  In Vivo .　　DOI:10.21873/invivo.12775.　

• Poor tolerability of lenvatinib in elderly patients ≥80 years old with hepatocellular carcinoma: A multicenter observational study
  Akiyoshi Kinoshita, Noriko Hagiwara, Akiyuki Osawa, Takafumi Akasu, Yoshihiro Matsumoto, Kaoru Ueda, Chisato Saeki, Tsunekazu Oikawa, Kazuhiko Koike, Masayuki Saruta
  J Oncol Pharm Pract .　　DOI:10.1177/10781552221077039　

• Prostaglandin E-Major Urinary Metabolite Diagnoses Mucosal Healing in Patients with Ulcerative Colitis in Remission Phase
  Toshiyuki Sakurai, Yoshihiro Akita, Haruna Miyashita, Ryosuke Miyazaki, Yuki Maruyama, Tomoko Saito, Mariko Shimada, Takuji Yamasaki, Seiji Arhihiro, Tomohiro Kato, Tomokazu Matsuura, Masahiro Ikegami, Isao Okayasu, Masayuki Saruta
  J Gastroenterol Hepatol . 2022 Jan 22　　DOI:10.1111/jgh.15782